Skip to content

Assessment of the influence of severe renal impairment on the pharmacokinetics of mirodenafil in Korean male volunteers

Document Type
Publications · Journal Article
Registered DB
SCIEScopus
Journal Ranking
JCR Q4Scopus Q2
Citation
Web of Science 3
JCR IF
JCR 2011 1.183
ISSN
0946-1965

Authors

  1. Noh, Yook-HwanFirst authorDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  2. Lim, Hyeong-SeokDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  3. Cho, Sang-HeonDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  4. Ghim, Jong-LyulDepartment of Clinical Pharmacology, Busan Paik Hospital, South Korea
  5. Choe, SangminClinical Trials Center, Pusan National University Hospital, South Korea
  6. Jung, Jin AhDepartment of Clinical Pharmacology and Therapeutics, Samsung Medical Center, South Korea
  7. Kim, Mi JoDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  8. Kim, Yo HanDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  9. Jin, Seok-JoonDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea
  10. Kim, Soon BaeDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
  11. Park, Jung SikDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
  12. Lee, Sang KooDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
  13. Yang, Won SeokDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
  14. Chang, Jai WonDepartment of Nephrology, University of Ulsan, Asan Medical Center, South Korea
  15. Lee, BongyongLife Science RandD Center, SK Chemical Co. Ltd., South Korea
  16. Bae, Kyun-SeopCorresponding authorDepartment of Clinical Pharmacology and Therapeutics, University of Ulsan, Asan Medical Center, South Korea

Abstract

Objective: To evaluate and compare the pharmacokinetics and tolerability of a single oral dose of mirodenafil in volunteer patients with severe renal impairment and healthy volunteers. Methods and materials: This open-label, single-dose, parallel-group clinical study enrolled a total 12 volunteers (6 healthy volunteers and 6 volunteer patients with severe renal impairment). Each volunteer was orally administered 50 mg mirodenafil and serial blood samples were obtained after drug administration to determine the plasma concentration of mirodenafil using LC-MS/MS. The measured individual plasma concentrations were used to calculate the pharmacokinetic parameters using noncompartmental methods. Tolerability was also assessed using measurements of vital signs, clinical chemistry tests, and interviews. Results: All of the volunteers completed the study with no serious adverse events (AEs). A total of 4 AEs were reported, but all were of mild or moderate intensity and not considered to be related to the study drug. The geometric mean (95% CI) of the terminal half-life (t(1/2 beta)) and the apparent clearance (CL/F) values of mirodenafil were 2.2 (1.4 - 3.4) hours and 127.2 (95.1 - 170.2) 1/h in the volunteer patients, and 3.0 (2.1 - 4.4) hours and 136.1 (74.4 - 249.2) 1/h in the healthy volunteers, respectively. The geometric mean of the AUC(0-t) of the volunteer patients was 8% higher and the geometric mean for clearance was 7% lower compared with the healthy volunteers. However, the geometric mean of the C-max of the volunteer patients was 38% higher than that of the healthy volunteers. Conclusions: A single oral 50-mg dose of mirodenafil was well tolerated. Exposure (AUC(0-t)) to mirodenafil was similar in both healthy volunteers and volunteer patients with severe renal impairment and healthy volunteers.

Keywords

mirodenafilphosphodiesterase 5 (PDE5) inhibitorrenal impairmentpharmacokineticshealthy volunteersERECTILE DYSFUNCTION5 INHIBITORSK3530EFFICACYSAFETYMEN

Identifiers

WoS UID
000313595100005